Contents

1 Introduction: The Rationale for the Development of Targeted Drugs in Cancer Therapy
Bernd Groner ................................................................. 1

2 Identifying Critical Signaling Molecules for the Treatment of Cancer
Constadina Arvanitis, Pavan Bendapudi, Pavan Bachireddy, and Dean W. Felsher .............. 5

3 Tyrosine Kinase Inhibitors and Cancer Therapy
Srinivasan Madhusudan and Trivadi S. Ganesan .............. 25

4 Targeting ERBB Receptors in Cancer
Nancy E. Hynes ............................................................... 45

5 Inhibition of the IGF-I Receptor for Treatment of Cancer. Kinase Inhibitors and Monoclonal Antibodies as Alternative Approaches
Yan Wang, Qun-sheng Ji, Mark Mulvihill, and Jonathan A. Pachter ........................................ 59

6 Inhibition of the TGF-β Signaling Pathway in Tumor Cells
Klaus Podar, Noopur Raje, and Kenneth C. Anderson ........ 77

7 The Mammalian Target of Rapamycin Kinase and Tumor Growth Inhibition
Anne Boulay and Heidi A. Lane ........................................ 99
8  The Ras Signalling Pathway as a Target in Cancer Therapy
    Kathryn Graham and Michael F. Olson .......................... 125

9  The Mitogen-Activated Protein Kinase Pathway
    for Molecular-Targeted Cancer Treatment
    Judith S. Sebolt-Leopold, Roman Herrera, and
    Jeffrey F. Ohren .................................................. 155

10  Clinical Relevance of Targeted Interference with
    Src-Mediated Signal Transduction Events
    Quan P. Ly and Timothy J. Yeatman ......................... 169
Targeted Interference with Signal Transduction Events
Groner, B. (Ed.)
2007, IX, 188 p., Hardcover
ISBN: 978-3-540-31208-6